This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Interventions
The analysis considered eight screening strategies that differed in the choice of the screening test and the number of screening rounds. The two screening tests were cytology and HPV DNA. There were seven, six, five, or four screening rounds, corresponding to intervals of five, six, 7.5, or 10 years, between the ages of 30 and 60 years. Vaccination alone was the reference scenario.
The usual care was cytology screening once every five years (seven rounds). Vaccination against HPV 16 and 18 was considered for the main analysis (with or without cross-protection), with vaccination against five (16, 18, 31, 33, and 45) to 13 types of HPV in secondary analyses.
Location/setting
Netherlands/primary care.
Methods

Analytical approach:
The analysis was based on an individual-level simulation of the relationship between 14 HPV types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) and cervical disease, including multiple types of infection. Women were modelled from the age 10 years, over their lifetime. The authors stated that the analysis took a societal perspective.
Effectiveness data:
The data were from published clinical trials, longitudinal studies, and epidemiological databases. Most of the data for HPV prevalence and the screening characteristics were from a randomised controlled population-based screening study, Population Based Screening Study Amsterdam (POBASCAM), that included 44,102 Dutch women aged between 29 and 61 years. Disease progression was from the POBASCAM and observational studies. Some assumptions were made. Vaccine efficacy and cross-protection were key inputs for the model and were from Phase III clinical trials.
Monetary benefit and utility valuations:
The utility values were from published sources. 
Measure of benefit:
Quality-adjusted life-years (QALYs) were the summary benefit measure and they were discounted at an annual rate of 1.5%. Life-years were considered in a sensitivity analysis.
Cost data:
The economic analysis included both the direct and indirect costs of vaccination, screening, and the management of disease, as well as productivity losses and travel expenses. These economic data were from published sources. All costs were in Euros (EUR) and a 4% annual discount rate was applied. The price year was 2009.
Analysis of uncertainty:
One-way sensitivity analyses were carried out on selected inputs for the model, using alternative assumptions based on published evidence or authors' opinions.
Results
In a scenario with no cross-protection and vaccination against HPV 16/18, after excluding dominated strategies, which were more expensive and less effective than another strategy, the expected costs were EUR 441 with vaccination, EUR 485 with vaccination plus cytology four times, EUR 505 with HPV DNA four times, EUR 521 with HPV DNA five times, and EUR 537 with HPV DNA six times. The QALYs were 42.6914 with vaccination, 42.7075 with cytology four times, 42.7104 with HPV DNA four times, 42.7111 with HPV DNA five times, and 42.7117 with HPV DNA six times.
Excluding the strategies with an incremental cost-utility ratio above the Dutch threshold of EUR 20,000 per QALY gained, the incremental cost per QALY gained was EUR 2,742 (EUR 4,986 with partial cross-protection against types 31, 33, 45 and 58) with cytology four times and EUR 6,707 (EUR 9,994 with partial cross-protection) with HPV DNA four times.
The same results were achieved when using international criteria for the discount rate (3% for both costs and benefits) and a cost-effectiveness threshold of EUR 37,000 per QALY gained based on gross domestic product per capita. In general, the results were confirmed in the sensitivity analysis when only vaccination against HPV 16/18 was considered, except when screening compliance was reduced from 80% to 40% (where seven rounds of DNA screening was the preferred option) or waning of vaccine induced immunity was introduced (and again seven rounds of DNA screening was the preferred option).
The cost-effectiveness results changed when a broad-spectrum of vaccination was assumed. With vaccination against five or more types of HPV, none of the screening options was cost-effective at the EUR 20,000 per QALY threshold. One screening in a lifetime was the only cost-effective option with vaccination against up to 11 types. The use of lifeyears gained instead of QALYs did not change the cost-effectiveness conclusions.
